InvestorsHub Logo
Followers 18
Posts 642
Boards Moderated 0
Alias Born 05/19/2017

Re: None

Sunday, 12/04/2022 1:40:42 PM

Sunday, December 04, 2022 1:40:42 PM

Post# of 461358
“Anavex has more than sufficient resources to complete its current trials: approximately $150 million in cash and cash equivalents…”

Considering the burn rate has been so minimal (extremely efficient use of resources), it’s not as if there’s any question of not completing any and all trials, whether ongoing, or scheduled.

The safety profile, efficacy, and involvement of transcriptomics analysis (RNAseq) have been executed very well.

As any long time shareholder of Anavex Life Sciences has noticed, the petty attacks (long haired doctor! printing company! not a real doctor! not a real banker! equivalent to coffee! bad math! goal posts! this quarter! that quarter! etc) are just that, petty.

SIGMACEPTOR is real as ‘phuq’ and patients have already benefited from its existence.

We’re in the catbird seat. PRÓST!
Bullish
Bullish
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News